Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations

Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations

Author Anuardo, Pedro Google Scholar
Verdier, Monica Google Scholar
Gormezano, Natali W. S. Google Scholar
Ferreira, Gabriela R. V. Google Scholar
Leal, Gabriela N. Google Scholar
Lianza, Alessandro Google Scholar
Ferreira, Juliana C. O. A. Google Scholar
Pereira, Rosa M. R. Google Scholar
Aikawa, Nadia E. Google Scholar
Terreri, Maria Teresa Autor UNIFESP Google Scholar
Magalhes, Claudia S. Google Scholar
Appenzeller, Simone Google Scholar
dos Santos, Maria Carolina Google Scholar
Sachetti, Silvana B. Google Scholar
Len, Claudio A. Autor UNIFESP Google Scholar
Pilleggi, Gecilmara S. Google Scholar
Lotufo, Simone Google Scholar
Bonfa, Eloisa Google Scholar
Silva, Clovis A. Google Scholar
Abstract The aim of this study was to evaluate pulmonary hypertension (PH) in 852 childhood-onset systemic lupus erythematosus (cSLE) patients. This was a large multicenter study conducted in 10 Pediatric Rheumatology Services of So Paulo state, Brazil. PH was defined as systolic pulmonary artery pressure > 35 mmHg and/or measurement of the mean pulmonary artery pressure > 25 mmHg and/or diastolic pressure > 15 mmHg by transthoracic echocardiogram. Demographic data, clinical manifestations, disease activity score (SLEDAI-2K), disease damage score (SLICC/ACR-DI) and treatments were also evaluated. Statistical analysis was performed using Bonferroni correction (p < 0.002). PH was observed in 17/852 (2%) cSLE patients. Effort dyspnea occurred in 3/17, chest pain in 1/17 and right ventricle dysfunction in 3/17 cSLE patients. None had pulmonary thromboembolism or antiphospholipid syndrome. Further comparison between 17 cSLE with PH and 85 cSLE control patients without PH with similar disease duration [15 (0-151) vs. 15 (0-153) months, p = 0.448], evaluated at the last visit, revealed higher frequencies of fever (47 vs. 9%, p < 0.001), reticuloendothelial manifestations (41 vs. 7%, p < 0.001) and serositis (35 vs. 5%, p = 0.001) in the former group. Frequencies of renal and neuropsychiatric involvements and antiphospholipid syndrome, as well as the median of SLEDAI-2K and SLICC/ACR-DI scores, were comparable in both groups (p > 0.002). Normal transthoracic echocardiography was evidenced in 9/17 (53%), with median cSLE duration of 17.5 months (1-40) after PH standard treatment. PH was a rare manifestation of cSLE occurring in the first two years of disease. The majority of patients were asymptomatic with mild lupus manifestations. The underlying mechanism seemed not to be related to pulmonary thromboembolism and/or antiphospholipid syndrome.
Keywords Pulmonary hypertension
Childhood systemic lupus erythematosus
Multicenter cohort
xmlui.dri2xhtml.METS-1.0.item-coverage New York
Language English
Sponsor Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
Federico Foundation
Nucleo de Apoio a Pesquisa "Saude da Crianc, a e do Adolescente'' da USP (NAP-CriAd)
Grant number CNPq: 301805/2013-0
CNPq: 303752/2015-7
CNPq: 301479/2015-1
CNPq: 305068/2014-8
CNPq: 303422/2015-7
Date 2017
Published in Pediatric Cardiology. New York, v. 38, n. 2, p. 234-239, 2017.
ISSN 0172-0643 (Sherpa/Romeo, impact factor)
Publisher Springer
Extent 234-239
Access rights Closed access
Type Article
Web of Science ID WOS:000395096700004

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account